Detalhe da pesquisa
1.
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.
Mol Cancer
; 22(1): 176, 2023 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37924050
2.
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.
Lung Cancer
; 166: 255-264, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953624
3.
Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer.
Clin Lung Cancer
; 23(6): e377-e383, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35660356
4.
An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer.
Eur Urol Oncol
; 3(4): 498-508, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31412010
5.
Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model.
Nat Commun
; 11(1): 1884, 2020 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32313004
6.
Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer.
Clin Cancer Res
; 25(22): 6671-6682, 2019 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31439588
7.
Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung Cancer.
JCO Precis Oncol
; 32019.
Artigo
em Inglês
| MEDLINE | ID: mdl-32914037